IRBs and the LRG Patient Registry
Institutional Review Boards (IRBs) are the core of the well-established U.S. system for the protection of human research participants.
Institutional Review Boards (IRBs) are the core of the well-established U.S. system for the protection of human research participants.
Having your GISTory or medical summary up to date and handy when faced with a medical emergency, is crucial to have on hand, when making decisions on how to proceed with your care.
We have put together a map showing the distribution of GIST patients in the U.S. who are living with GIST in the LRG Patient Registry by state. The map shows how geographically diverse the Patient Registry is, with patients spread throughout the country.
Join our Tissue Bank - Help the LRG in the search for a cure. Wildtype GIST tissue is needed for a current LRG Research Team project. If you or a loved one are a wildtype GIST patient, please help the LRG Research Team in its search for the cure by donating your tissue.
After two years of planning, toiling, and more planning, the LRG unveiled its redesigned website on January 1 at our same web address: liferaftgroup.org. Finding the balance between providing life-saving information and explaining GIST in a concise, understandable way, has always been a struggle for the Life Raft Group.
The LRG Research Team recently held a teleconference that focused primarily on a study the team will collaborate on and intends to publish.
The Life Raft Group’s Patient Registry gives GIST patients an opportunity to contribute to finding a cure by sharing information on their medical status, treatments and side effects. This information is kept in a comprehensive [...]
As of December 31, 2010 the Life Raft Group’s Patient Registry has now accounted for 1,279 cases of GIST. The members of this registry have reported their clinical information to us as it pertains to their treatment of GIST. Of these 1,279 cases, we are here to report some key demographics that will help you understand who is a part of Life Raft Group GIST Community.
The Gleevec for GIST story continues to remain one of the most successful stories in oncology. What could be better than a drug that works in 85 percent of patients? As great as this story is, there is room for improvement. Half of the patients on Gleevec for metastatic disease will progress in the first two years and 15 percent of patients are resistant to Gleevec right away or within the first six months of treatment. AROG Pharmaceuticals may have an option for a few of those patients.
The LRG uses registry & “GISTory” to help patients in a new way. Many of you who participate in the Life Raft Group’s Patient Registry may have received our monthly plea to help us update our [...]